Skip to main content

Lorena Ramos Pérez

Institutions of which they are part

Research technician
Diabetes and Metabolism
Vall Hebron Institut de Recerca

Lorena Ramos Pérez

Institutions of which they are part

Research technician
Diabetes and Metabolism
Vall Hebron Institut de Recerca

Projects

Mecanismos moleculares que regulan la sex hormone- binding globulin y sus implicaciones terapéuticas.

IP: David Martinez Selva
Collaborators: Lidia Fuertes Rioja, Maria Teresa Salcedo Allende, Lorena Ramos Pérez, Pablo Gabriel Medina
Funding agency: Instituto de Salud Carlos III
Funding: 147620
Reference: PI18/00320
Duration: 01/01/2019 - 31/12/2022

Función de la Sex Hormone-Binding Globulin en el Tejido Adiposo: Caracterización de la Expresión, Regulación e Implicaciones Terapéuticas.

IP: David Martinez Selva
Collaborators: Jose Manuel Fort López-Barajas, Lorena Ramos Pérez
Funding agency: Instituto de Salud Carlos III
Funding: 177265
Reference: PI15/00823
Duration: 01/01/2016 - 30/09/2019

Diabetis i Metabolisme (GRC)

IP: Rafael Simó Canonge
Collaborators: Josep A Villena Delgado, Carles Zafon Llopis, Cristina Hernández Pascual, David Martinez Selva, Andreea Ciudin Mihai, Lorena Ramos Pérez, Rosa Burgos Peláez, Olga Simó Servat, Patricia Bogdanov Baruj
Funding agency: Agència Gestió Ajuts Universitaris i de Recerca
Funding: 40000
Reference: 2014 SGR 270
Duration: 01/01/2014 - 31/12/2016

Mecanismos moleculares que regulan la expresión de la SHBG en la obesidad y en la distribución de la grasa corporal inducida por la dieta: implicaciones terapéuticas

IP: David Martinez Selva
Collaborators: M Luisa Chicharro Serrano, Andreea Ciudin Mihai, Lorena Ramos Pérez
Funding agency: Instituto de Salud Carlos III
Funding: 183315
Reference: PI12/01357
Duration: 01/01/2013 - 31/12/2015

Related news

Funding has been obtained for 43 projects under the calls for Health R&D&I Projects, Health Technology Development, and Independent Clinical Research

The work represents a paradigm shift in the clinical approach to this chronic, multifactorial disease, based on the clinical context of each patient and not only on weight loss.

The results of a phase 3 clinical trial show that orforglipron reduces body weight by an average of 11% and improves cardiovascular risk factors.

Related professionals

Cristina Díaz Amaral

Cristina Díaz Amaral

Predoctoral researcher
Reconstructive Surgery of the Locomotor System
Read more
Maria Pilar Redondo Gonzalez

Maria Pilar Redondo Gonzalez

Research assistant
Microbiology
Read more
Montse Rodriguez Gomez

Montse Rodriguez Gomez

Shock, Organ Dysfunction and Resuscitation
Read more
Laura Puente Ramo

Laura Puente Ramo

Liver Diseases
Read more

Subscribe to our newsletters and be part of the Campus life

We are a world-leading healthcare complex where healthcare, research, teaching and innovation go hand in hand.

This question is for testing whether or not you are a human visitor and to prevent automated spam submissions.